“We
aim to be world’s leading provider of vaccines,”
—Weidong Yin, chairman, president
& CEO, Sinovac Biotech, China
Sinovac Biotech, also
known in China as Beijing Kexing Bioproducts, specializes in
the research, development, commercialization, and sales of human
vaccines for infectious illnesses such as hepatitis A,
hepatitis B, influenza and SARS. Working closely with Chinese public
health officials, Sinovac focuses on manufacturing and marketing
human-use vaccines and related products. Sinovac is currently
developing a universal pandemic influenza vaccine and Japanese
encephalitis vaccine. Sinovac is the first and currently the only
company in the world to have been granted permission to begin clinical
trials for a vaccine to prevent SARS. Recently, as a testimonial to its
commitment towards quality products, the company has received
Good Manufacturing Practice (GMP) certification for its newly opened
filling and packaging production facility. In an interview with
BioSpectrum, Weidong Yin, chairman, president and CEO
of Sinovac Biotech, elaborates on the company’s
endeavors and the vaccine market in China.
What do you see as
Sinovac’s competitive advantage?
I believe, Sinovac has the management flexibility compared to big
companies. The company has multiple sources of financing as well as
standardized and transparent management through public listing in the
US stock market. The local production provides cost advantages. Full
understanding of market demands in China enables Sinovac to achieve
strong market penetration. Sinovac has strong R&D capabilities.
Compared with other Chinese companies, Sinovac is more open to
collaboration and it has a clear mission of targeting the improvement
of China’s public health.
What do you see as Sinovac’s competitive advantage?
I believe, Sinovac has the management flexibility compared to big
companies. The company has multiple sources of financing as well as
standardized and transparent management through public listing in the
US stock market. The local production provides cost advantages. Full
understanding of market demands in China enables Sinovac to achieve
strong market penetration. Sinovac has strong R&D capabilities.
Compared with other Chinese companies, Sinovac is more open to
collaboration and it has a clear mission of targeting the improvement
of China’s public health.
Can you elaborate on
the vaccine market in China as such and where Sinovac is positioned in
the industry?
China’s vaccine market can be divided into two sections,
namely the public market and private market. In the public market,
vaccines are mainly purchased by the central government. Both central
and local governments provide centralized financial allocations for the
public market. In the private market, the purchases are made by
individuals, and include Sinovac’s adult and pediatric
vaccines. In addition, the private market also includes vaccines for
special groups, such as rabies vaccines and hemorrhagic fever vaccine.
The vaccine market in China is expanding rapidly. Since the open of the
private market, domestic vaccine market has grown at a 15 percent
annual growth rate, which is much higher than global average number of
10 percent. The market scale in 2006 was about Rs 3.34 lakh crore ($670
million), of which more than Rs 1.93 lakh crore ($388 million) came
from the private market. With the public’s increasing
attention to vaccination, the private market is expected to continue to
develop rapidly. In addition, purchases from the government and the
development of novel vaccines (improved vaccines) are encouraging the
development of the vaccine market. It is estimated that the annual
growth rate will be more than 20 percent in the future. By 2010,
China’s vaccine market scale may achieve Rs 7,312-8,777 crore
(10—12 billion RMB).
Sinovac is a leading vaccine biological company, and the largest
supplier of hepatitis A inactivated vaccines in China. We enjoy
advantages in the R&D, standardized management and financing
capability.Ajeesh Anand
How strong is your
customer base in China? What are the other markets in focus?
In the market of planned immunization, China has a huge base of
population of more than 130 crore. Vaccine usage is changing with the
fluctuation of the annual birth rate. There is a big potential
developing market with 1.5 crore newborns each year. Regarding the
private market, Sinovac’s principal consumers are the
20—30 crore people living in developed areas.
Sinovac has in-house sales team, including 91 sales professionals
covering 30 provinces and cities in China. Other than China, Sinovac
plans to export products to developing countries. Currently, we are
exploiting international markets with two of our products, hepatitis A
vaccine and influenza vaccine.
Ajeesh Anand
Can you update us on
your product pipeline? Please elaborate on the status of Japanese
encephalitis, H5N1 and SARS vaccines?
Currently, we have disclosed six projects in our pipeline, namely
universal pandemic influenza vaccine, EV71 (hand, foot and mouth
disease) vaccine, hepatitis C vaccine, JE (Japanese Encephalitis)
vaccine, rabies vaccine and pandemic influenza vaccine. Our R&D
team actively provides momentum to project development. Since the
R&D process of vaccines is relatively complex and long-term
work, Sinovac plans to launch one or two products each year during 2012
and 2020.
Pandemic influenza whole virus inactivated vaccine, Panflu, obtained a
production license from the China SFDA in April 2008. We have also
completed volunteer enrollment for the split pandemic influenza
inactivated vaccine in the third quarter of 2008. Sinovac anticipates
the preliminary results in early 2009.
The Japanese Encephalitis vaccine is in the preclinical research stage.
We believe our production technology can increase manufacturing yield,
simplify operations and stabilize cultivation conditions, all of which
facilitate large-scale automated production. We had
completed phase-I clinical trial for SARS vaccine in December 2004.
Recently Sinovac has
received approval from China’s Ministry of Agriculture to
conduct trials of rabies vaccine. Can you throw more light on this? How
do you see the market opportunities for veterinary vaccines in China?
Sinovac’s wholly owned subsidiary, Tangshan Yian Biological
Engineering Co, is entering the veterinary vaccine market in China by
developing a domestically produced inactivated rabies vaccine which
will be one of the first inactivated versions to be developed in China.
We anticipate that the field trials for the inactivated animal rabies
vaccine will take approximately nine months to complete and that the
vaccine will be launched in China’s veterinary market in
2010. The move indicates that, while Sinovac will maintain its leading
position in the human vaccine market, the company is expanding into a
related business area that allows it to leverage its core competencies
in vaccine R&D and production. Tangshan Yian obtained approval
from China’s Ministry of Agriculture to conduct field trials
of its internally developed inactivated animal rabies vaccine with
independent intellectual property rights in early 2009.
Farming output in China is significant and rapidly growing. Given the
human health hazards associated with animal diseases, China’s
government is raising investment in the prevention and control of
animal diseases. From 2000-08, foot and mouth disease, bird flu, swine
fever and swine blue ear disease have been included in the compulsory
vaccination program. The compulsory vaccination program has lead to the
creation of a number of animal health enterprises with an annual value
of over Rs 364.43 crore (500 million RMB). The Chinese government
continues to expand the scope of the veterinary vaccination program.
Huge farming output and the expanding veterinary vaccination program
are creating market opportunities.
What are the major
challenges from the industry? What is your strategy to tackle those
challenges?
I believe the major challenges for the vaccine industry are linked with
the challenges to human health. Our mission is to supply vaccines to
eliminate human diseases. Our major challenges are meeting the
public’s demand for safe and effective vaccines against
diseases, like SARS and bird flu. We are in a leading
position in the research and development of vaccines. At the outbreak
of SARS, we are the first and only company to have completed phase I
clinical trials. When human cases of the H5N1 virus are reported, we
promptly advanced the R&D of a vaccine against the virus. In
other words, Sinovac’s strategy is to monitor our R&D
capabilities and to increase investment on R&D. More
importantly, since we put efforts into cost control, we can supply high
quality vaccines at a relatively low cost.
What sort of impact
Sinovac has due to the global economic crisis? How do you see the
future of Sinovac?
China is also affected by the global financial crisis that hit the
world in 2008. The biopharmaceutical industry relates to
people’s livelihood, though demand for biopharmaceutical
products is somewhat rigid. The biopharmaceutical industry is less
affected by macro-economy, but rather controlled and affected by
industry policies. Under the shadow of the dim world economic view, the
crisis has had a relatively small influence over the biopharmaceutical
industry. Sinovac’s operation has not been affected by the
crisis.
Since Chinese citizens are increasing their standards for health and
quality of life, and the Chinese government is gradually increasing its
support for innovative enterprises, space for development of
Sinovac will enlarge accordingly. The ultimate objective of Sinovac is
to become a leading provider of vaccines in the world.
Ajeesh Anand